Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 14/20 | 0.32 |
| ▸ | P2RY4 | P51582 | 6/20 | 0.32 |
| ▸ | RNASEL | Q05823 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | POLA1 | P09884 | 1/20 | 0.31 |
| ▸ | POLD1 | P28340 | 1/20 | 0.31 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.31 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.31 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24730958 | 0.88 | P2RY2 (0.30) | P2RY2P2RY4POLBPOLA1POLD1 | |
| SCHEMBL23197870 | 0.88 | P2RY2 (0.30) | P2RY2P2RY4POLBPOLA1POLD1 | |
| SCHEMBL23197957 | 0.86 | POLB (0.36) | P2RY2P2RY4RNASELPOLBPOLA1 | |
| SCHEMBL271990 | 0.82 | P2RY2 (0.37) | P2RY2P2RY4POLBPOLA1POLD1 | |
| SCHEMBL272516 | 0.78 | P2RY2 (0.36) | P2RY2P2RY4POLBPOLA1POLD1 | |
| SCHEMBL25141885 | 0.78 | P2RY2 (0.37) | P2RY2P2RY4POLBPOLA1POLD1 | |
| SCHEMBL18462970 | 0.77 | P2RY2 (0.35) | P2RY2P2RY4RNASELPOLBPOLA1 | |
| SCHEMBL271873 | 0.77 | P2RY2 (0.35) | P2RY2P2RY4POLBPOLA1POLD1 | |
| SCHEMBL22002630 | 0.77 | P2RY2 (0.37) | P2RY2P2RY4POLBPOLA1POLD1 | |
| SCHEMBL21555519 | 0.77 | P2RY2 (0.37) | P2RY2P2RY4POLBPOLA1POLD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220389049-A1 | REVERSIBLE TERMINATORS FOR DNA SEQUENCING AND METHODS OF USING THE SAME | CENTRILLION TECHNOLOGY HOLDINGS CORPORATION (VG) | 2022-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220389049-A1 | REVERSIBLE TERMINATORS FOR DNA SEQUENCING AND METHODS OF USING THE SAME | RNGTT, NT5C3B, NSUN2 | P2RY2 2614/4885P2RY4 1458/4885RNASEL 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.